Hereditary Hemorrhagic Telangiectasia (HHT) Center

The Hereditary Hemorrhagic Telangiectasia Center funding opportunity is administered by the Health Resources and Services Administration within the U.S. Department of Health and Human Services through its Maternal and Child Health Bureau. This program is designed to support a single national center focused on improving care and outcomes for individuals affected by Hereditary Hemorrhagic Telangiectasia, a rare genetic disorder characterized by abnormal blood vessel formation that can lead to severe complications including stroke, bleeding, and organ damage. The initiative reflects federal priorities to expand coordinated, multidisciplinary care and strengthen national systems addressing rare and chronic conditions. The primary purpose of the program is to reduce illness and mortality associated with HHT by building and coordinating a national network of at least fifteen specialized clinical centers. These centers are expected to provide comprehensive evaluation, treatment, and education for patients and their families while participating in collaborative quality improvement initiatives. A central component of the program includes the development and maintenance of a national patient data registry to better understand disease progression, improve diagnosis, and inform treatment strategies. The funded entity will also pilot electronic health record enhancements to support early identification and management of HHT cases. Funding for this opportunity is structured as a cooperative agreement, with an expected total program funding of 2900000 dollars for fiscal year 2026. Only one award is anticipated, supporting a project period spanning three years from September 1, 2026 through August 31, 2029. The program does not require cost sharing or matching funds, although voluntary contributions are allowed but not considered during application review. Funds must be used in alignment with federal regulations and restrictions, including prohibitions on certain activities and strict adherence to allowable cost principles. Eligible applicants include domestic organizations such as state governments, public and private institutions, and other eligible entities located within U.S. states and territories. Individuals are explicitly excluded from eligibility. Applicants must demonstrate the capacity to manage complex, multi-site clinical collaborations, oversee data systems compliant with federal privacy and cybersecurity standards, and implement nationwide quality improvement initiatives. Applications must meet strict completeness and eligibility requirements, including submission deadlines, page limits, and funding thresholds. The application process requires submission through Grants.gov and includes multiple components such as a project narrative, budget narrative, work plan, staffing plan, and supporting documentation including agreements with participating clinical centers. Applicants must also register with SAM.gov and maintain active credentials. Evaluation criteria are comprehensive and include assessment of need, program design, performance measurement, organizational capacity, and budget justification. Reviewers will prioritize proposals demonstrating strong collaboration, data management capabilities, and measurable impact on patient outcomes. Key dates for this opportunity include a notice of funding release on June 8, 2026, an application deadline of July 10, 2026, and an expected award date of August 2, 2026, with project activities beginning September 1, 2026. Applications must be submitted by 11:59 PM Eastern Time on the deadline date. There is no indication that this opportunity is recurring, and applicants are advised to adhere strictly to submission guidelines to avoid disqualification. Post-award, the recipient will be required to engage closely with HRSA through ongoing monitoring, reporting, and collaboration. Responsibilities include annual performance reporting, participation in federal oversight activities, and dissemination of findings through publications and presentations. The program emphasizes long-term sustainability, requiring applicants to outline strategies for continuing key activities beyond the federal funding period. Contact information for programmatic and financial inquiries is provided within the notice, including designated HRSA staff responsible for supporting applicants throughout the process.

Focus on strong clinical partnerships data registry design and measurable outcomes ensure compliance with interoperability and privacy standards and clearly demonstrate national impact and sustainability